
DexCom (DXCM): Growth Broadens, but Valuation Limits Upside
DexCom posted 13% Q2 revenue growth, 46% EPS growth, and raised 2026 guidance, but the stock still screens as a Hold at a rich valuation. The report highlights expanding reimbursement, strong G7 15 Day adoption, and a growing opportunity in non-insulin type 2 diabetes.



